TruSpine Technolgs. - Loan repayment & Update

Announcement provided by

TruSpine Technologies Plc · TSP

28/06/2023 12:13

RNS Number : 2606E

TruSpine Technologies PLC

28 June 2023

TruSpine Technologies plc

("TruSpine" or the "Company")

Loan repayment & Update

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that, further to the announcement on 25 April 2023, the Company has repaid the £100,000 loan and accrued interest under the Loan Agreement with Annabel Schild. The Funding Loan was repaid from existing cash resources following receipt of a HMRC R&D tax credit of approximately £200,000 ("Tax Credit").

Update on Working Capital

The Company has limited working capital resources and continues to carefully manage its cash position.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 25 April 2023.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

TruSpine Technologies Plc	Tel: +44 (0)20 7118 0852
Laurence Strauss, Chief Executive Officer

Cairn Financial Advisers LLP (AQSE Corporate Adviser)	Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Oberon Capital (Joint Broker)	Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford
Peterhouse Capital Limited (Joint Broker & Financial Adviser)	Tel: +44 (0)20 7469 0930
Lucy Williams / Duncan Vasey
Novus Communications (PR and IR)	Tel: +44 (0)20 7448 9839
Alan Green / Jacqueline Briscoe	novuscomms@truspine.org

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXNKFBDDBKDKAB ]]>

TSP announcements All announcements